We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/xiuning…

📖 🔥New online from our group at @UTMDAnderson on ultra-precision oncology in #lungcancer 👉 Analysis from over 22,000 #EGFR-mutant tumor samples identified #PACC mutations in 12% of cases (A) 👉 While classical and #Ex20 mutations more commonly occur as single mutations, PACC mutations are more frequently (66%) observed as compound mutations (B). 👉 PACC/PACC and PACC/classical-like compound mutations function biologically similar to single PACC mutations, NOT classical mutations (C) 👉 Compound PACC mutations demonstrate greater sensitivity to EGFR TKIs than single PACC mutations (D) ⚡ 💡 Largest #EGFR mutation landscape in a Western population. ⚡ 💡 #Compound EGFR PACC Eare biologically analogous to #single PACC. ⚡ 💡 Important insights for drug development of next-generation EGFR TKIs.

How should we structure future discussions to better address shifting paradigms in thoracic oncology? For the 8th consecutive year, @peters_solange and @Alfdoc2 will co-chair the ILCS 2026. Bringing decades of clinical expertise from @OncoUNILCHUV & @hug_ge, they will guide the discussion on the most critical clinical developments and treatment algorithms in NSCLC and SCLC. Join them live on 13ᵗʰ November and get registered ⬇️ lungsummit.org/#ILCS

Quite a whirlwind at #ASCO26 with lung cancer updates. For highlights from targeted therapy, Dr. @NarjustFlorezMD and I spoke with Drs. Alice Shaw and Jonathan Goldman for the @IASLC podcast, Lung Cancer Considered. Listen today! #ALK #RET #EGFR iaslc.org/iaslc-news/lung-ca…

Published by @VJHemOnc vjhemonc.com/video/9-vxtzv-k…

Published by @VJHemOnc vjhemonc.com/video/0aiqea_6s…

3/ @Alfdoc2 on secondary endpoints (TRITON) at #ASCO26: x.com/Alfdoc2/status/2060797…

@DmuDubai poster is up ! Great collaboration with an amazing team :-)

DART study 🎯 showed responses in 31 (if I counted correctly) different rare tumor types with ipi nivo. So important for patients with rare cancers. Amazing effort by @Dr_R_Kurzrock @PatelOncology @SWOG supported by @theNCI @NCIDirector #ASCO26

Amazing collaboration with my friends @DmuDubai

@Alfdoc2, this is what is all about !

Negative phase III trial of concurrent thoracic RT in ES-SCLC receiving chemoimmunotherapy. TRT was initiated early (between cycles 2 and 3), and failed to improve outcomes: • Median OS 10.0 vs 11.8 months • No improvement in response rate • More adverse events and treatment-related deaths While disappointing, these results should not be extrapolated to all consolidative TRT strategies. One key difference from SAKK 15/19 is timing: RT here was delivered concurrently with ongoing chemoimmunotherapy, whereas SAKK 15/19 administers TRT after completion of induction treatment and no major toxicity was detected Perhaps the lesson is not that thoracic RT has no role, but that timing matters. pubmed.ncbi.nlm.nih.gov/4134… #ASCO26 #SCLC #LungCancer #Radiotherapy

Bravo au Dr Thibaud Koessler @hug_ge pour cette intervention claire et nuancée sur la RTS. Dans un domaine où les messages sont souvent simplifiés à l’extrême, il est essentiel de rappeler à la fois les progrès remarquables réalisés en oncologie et les défis qui restent à relever pour nos patients. 🎗️ Merci de porter la voix de la science et de la médecine fondée sur les preuves dans le débat public. rts.ch/play/tv/forum/video/f… #Cancer #Oncologie #RTS #RechercheClinique

#ASCO2026 | LORIN Phase II Neoadjuvant lorlatinib in stage III ALK NSCLC delivered impressive results: pCR 47%,MPR 81%,ORR 84%, 75% surgical conversion in initially unresectable disease Small, single-arm study? Absolutely. Randomized confirmation needed? Of course.Practice changing? Debatable. But if I see a stage III ALK patient tomorrow, these data would be very hard for me to ignore. I probably wouldn’t hesitate to discuss a neoadjuvant ALK-directed approach at the MDT. #LungCancer #NSCLC #ALK #Lorlatinib #PrecisionOncology #ASCO26

It is always fantastic to bump in to colleagues while wandering at the #asco2026 @VivekSubbiah

Registration for International Lung Cancer Summit 2026 is now open. Join co-chairs @peters_solange and @Alfdoc2 on the ILCS to discuss how the latest trial data impacts everyday clinical decisions. This is your opportunity to connect with colleagues and debate real-world treatment strategies for advanced NSCLC and SCLC. 🗓️ Friday, November 13ᵗʰ, 2026 📍 Lausanne, Switzerland & Live Online Secure your spot here ⬇️ lungsummit.org/#ILCS

One of the most awaited presentations( at least by me) #ASCO26: HARMONi-6 shows that ivonescimab chemo significantly improves OS Vs tislelizumab chemo in first-line advanced Sq #NSCLC (HR 0.66). A positive phase III study with a clinically meaningful OS benefit and simultaneous publication in @TheLancet: thelancet.com/journals/lance… Caveat: this was a study conducted entirely in China. How these data will translate globally remains an important question? Let’s see what HARMONI 3 will show

In the phase III #LIBRETTO432 trial, adjuvant #selpercatinib improved event-free survival in resected stage IB–IIIA #RET fusion-positive #NSCLC. HR 0.17, with only 4 events vs 19 in the placebo arm.Overall survival remains immature, but today it is difficult not to be impressed by these data. Practice changing with no hesitation whatsoever #LungCancer #RET #TargetedTherapy #PrecisionMedicine #ASCO2026

The #WNTD 2026 theme, “Unmasking the appeal: Countering nicotine and tobacco addictions” highlights the industry strategies used to bypass established regulations. Policy makers and healthcare workers must look beyond traditional tobacco to address how new products drive dependence, ensuring our advocacy focuses on systemic accountability rather than patient stigma.

REVOL858R delivers a clear message: sequential EGFR inhibition with erlotinib ramucirumab followed by osimertinib did not improve the primary endpoint (TFS) compared with upfront osimertinib in EGFR L858R-mutated advanced NSCLC. Median TFS: Osimertinib: 14.8 months Vs Erlotinib ramucirumab → osimertinib: 16.6 months HR 1.03, p=0.49 Interesting concept, but in practice the strategy failed to outperform upfront osimertinib. #LungCancer #NSCLC #EGFR #Osimertinib #ThoracicOncology #ASCO2026 #PrecisionOncology